Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells

Lanzilli, Giulia; Traggiai, Elisabetta; Braido, Fulvio; Garelli, Valentina; Folli, Chiara; Chiappori, Alessandra; Riccio, Anna Maria; Bazurro, Gyada; Agazzi, Alessia; Magnani, Alessandra; Canonica, Giorgio Walter; Melioli, Giovanni

doi:10.1016/j.imlet.2012.11.009

Cited by 23 publications

(29 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…51 It was suggested that bacterial lysates act by increasing the number of circulating effector T and natural killer cells, thereby limiting the severity of life-threatening infections in these patients. 38 More recent European systematic reviews have shown that bacterial lysates lower the frequency of COPD. 52e54 An RCT carried out as part of an ongoing multicenter trial investigated serum viral antibody conversion rates as markers for polyclonal B-cell activation, and preliminary findings indicated that patients treated with bacterial lysates exhibit potentiation of humoral immune responses across a broad spectrum against so-called memory antigens.…”

Section: Clinical Outcomes Of Bacterial Lysate Therapy In Adult Respimentioning

confidence: 99%

Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma

Kearney

Dziekiewicz

Feleszko

2015

Annals of Allergy, Asthma & Immunology

107

View full text Add to dashboard Cite

Section: Clinical Outcomes Of Bacterial Lysate Therapy In Adult Respimentioning

confidence: 99%

Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma

Kearney

Dziekiewicz

Feleszko

2015

Annals of Allergy, Asthma & Immunology

107

View full text Add to dashboard Cite

“…CD8+ and CD25 + T-cell subsets were unaffected, while the number of Treg cells was reduced and the number of circulating NK cells increased significantly. The authors suggested that these results are indicative of a broad immune response to PMBL involving polyclonal activity [132].…”

Section: Copd/chronic Bronchitismentioning

confidence: 98%

Immunoactive preparations and regulatory responses in the respiratory tract: potential for clinical application in chronic inflammatory airway diseases

Feleszko

Rossi

Krenke

et al. 2020

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Introduction: The prevalence of chronic inflammatory airway diseases is rising. Their treatment with corticosteroids increases infection risk, while overuse of antimicrobial agents may increase morbidity and antimicrobial resistance. Nonspecific immunomodulatory compounds alter immune responses to both infectious and atopic challenges. These compounds may offer an alternative approach for symptom reduction and prophylaxis against both infections and exacerbations in chronic inflammatory airway disease. Areas covered: We assessed the available data on the efficacy of nonspecific immunomodulators including bacterial lysates, synthetic compounds, and vaccines in chronic rhinosinusitis (CRS); allergic and non-allergic rhinitis; chronic obstructive pulmonary disease (COPD), and asthma. A search of PubMed was carried out using the 'Clinical Trials' filter for each condition and immunomodulatory product detailed below, where available, data from meta-analyses were reported. Expert opinion: Pre-clinical data has revealed a coherent mechanistic path of action for oral immunomodulators on the respiratory immune system, principally via the gut-lung immune axis. In patients with asthma, allergic rhinitis, CRS, and COPD immunomodulatory therapy reduces symptoms, exacerbations, hospitalizations, and drug consumption. However, data are heterogeneous, and study quality remains limited. A lack of high-quality recent trials remains the major unmet research need in the field. ARTICLE HISTORY

show abstract

“…Starting from these lines of evidence, different bacterial lysates were shown to be able to induce significant activation and maturation of DC in vitro [7,8]. More recently, using a specific member of the bacterial lysate family (the Polyvalent Mechanical Bacterial Lysate -PMBL), other relevant effects were observed on B cells, T cells and NK cells [9,10] and these effects were also correlated with the clinical results [11,12]. Bacterial lysates are obtained by physical or chemical lysis.…”

Section: Introductionmentioning

confidence: 99%

“…Lantigen B belongs to the latter family, being a suspension of bacterial antigens obtained from Streptococcus pneumoniae type 3, Streptococcus pyogenes Group A, Branhamella catarrhalis, Staphylococcus aureus, Hemophilus influenzae type b and Klebsiella pneumoniae. The in vivo effects of Lantigen B were first described in the mid 1970s [11][12][13]. Since that time, few studies have been performed on this specific drug.…”

Section: Introductionmentioning

confidence: 99%

The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial

Braido

Melioli

Candoli³

et al. 2014

Immunology Letters

Self Cite

View full text Add to dashboard Cite

Studies in the 1970s and 1980s reported that bacterial lysates (BL) had a prophylactic effect on recurrent respiratory tract infections (RRTI). However, controlled clinical study procedures have evolved substantially since then. We performed a trial using updated methods to evaluate the efficacy of Lantigen B®, a chemical BL. This double blind, placebo controlled, multi-center clinical trial had the primary objective of assessing the capacity of Lantigen B to significantly reduce the total number of infectious episodes in patients with RRTI. Secondary aims were the RRTI duration, the frequency and the severity of the acute episodes, the use of drugs and the number of missed workdays. In the subgroup of allergic patients with RRTI, the number of allergic episodes (AE) and the use of anti-allergic drugs were also evaluated. One hundred and sixty patients, 79 allocated to the treated group (TG) and 81 to the placebo group (PG), were enrolled; 30 were lost during the study and 120 (79 females and 38 males) were evaluated. The PG had 1.43 episodes in the 8-months of follow-up while the TG had 0.86 episodes (p=0.036). A similar result was observed in the allergic patients (1.80 and 0.86 episodes for the PG and the TG, respectively, p=0.047). The use of antibiotics was reduced (mean 1.24 and 2.83 days of treatment for the TG and the PG). Logistic regression analysis indicated that the estimated risk of needing antibiotics and NSAIDs was reduced by 52.1 and 30.6%, respectively. With regard to the number of AE, no significant difference was observed between the two groups, but bronchodilators, antihistamines and local corticosteroids were reduced by 25.7%, 56.2% and 41.6%, respectively, in the TG. Lantigen B significantly reduced the number of infectious episodes in patients with RRTI. This finding suggests a first line use of this drug for the prophylaxis of infectious episodes in these patients.

show abstract

Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells

Cited by 23 publications

References 24 publications

Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma

Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma

Immunoactive preparations and regulatory responses in the respiratory tract: potential for clinical application in chronic inflammatory airway diseases

The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial

Contact Info

Product

Resources

About